Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Debt (2016 - 2025)

Historic Total Debt for Viridian Therapeutics, Inc.\DE (VRDN) over the last 9 years, with Q3 2025 value amounting to $20.9 million.

  • Viridian Therapeutics, Inc.\DE's Total Debt rose 178.82% to $20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 178.82%. This contributed to the annual value of $20.6 million for FY2024, which is 186.59% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Total Debt stood at $20.9 million for Q3 2025, which was up 178.82% from $20.8 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Total Debt high stood at $20.9 million for Q3 2025, and its period low was $20.2 million during Q4 2023.
  • Moreover, its 3-year median value for Total Debt was $20.6 million (2024), whereas its average is $20.6 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Total Debt skyrocketed by 186.59% in 2024, and later soared by 164.78% in 2025.
  • Quarter analysis of 3 years shows Viridian Therapeutics, Inc.\DE's Total Debt stood at $20.2 million in 2023, then increased by 1.87% to $20.6 million in 2024, then rose by 1.5% to $20.9 million in 2025.
  • Its Total Debt stands at $20.9 million for Q3 2025, versus $20.8 million for Q2 2025 and $20.7 million for Q1 2025.